KR20220156534A - 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법 - Google Patents

고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220156534A
KR20220156534A KR1020227030919A KR20227030919A KR20220156534A KR 20220156534 A KR20220156534 A KR 20220156534A KR 1020227030919 A KR1020227030919 A KR 1020227030919A KR 20227030919 A KR20227030919 A KR 20227030919A KR 20220156534 A KR20220156534 A KR 20220156534A
Authority
KR
South Korea
Prior art keywords
arginine
pharmaceutical formulation
concentration
ser
ban2401
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227030919A
Other languages
English (en)
Korean (ko)
Inventor
노부오 요시다
나오미 사쿠라모토
다카히사 사카구치
히로카즈 기토
다카히로 오자와
안잘리 조시
융 웨 쑤
피에르 수이약
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20220156534A publication Critical patent/KR20220156534A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
KR1020227030919A 2020-03-20 2021-03-19 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법 Pending KR20220156534A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US62/992,746 2020-03-20
US202063027263P 2020-05-19 2020-05-19
US63/027,263 2020-05-19
PCT/IB2021/000155 WO2021186245A1 (en) 2020-03-20 2021-03-19 HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
KR20220156534A true KR20220156534A (ko) 2022-11-25

Family

ID=75746958

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030919A Pending KR20220156534A (ko) 2020-03-20 2021-03-19 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법

Country Status (27)

Country Link
US (1) US20230183328A1 (https=)
EP (2) EP4121007B1 (https=)
JP (2) JP7689141B2 (https=)
KR (1) KR20220156534A (https=)
CN (1) CN115315251A (https=)
AU (1) AU2021238951A1 (https=)
BR (1) BR112022018766A2 (https=)
CA (1) CA3174778A1 (https=)
CL (2) CL2022002517A1 (https=)
CO (1) CO2022012916A2 (https=)
DK (1) DK4121007T3 (https=)
ES (1) ES3041762T3 (https=)
FI (1) FI4121007T3 (https=)
HR (1) HRP20251087T1 (https=)
HU (1) HUE072937T2 (https=)
IL (2) IL295383B1 (https=)
LT (1) LT4121007T (https=)
MA (1) MA59082B1 (https=)
MD (1) MD4121007T2 (https=)
MX (1) MX2022011101A (https=)
PH (1) PH12022552172A1 (https=)
PL (1) PL4121007T3 (https=)
PT (1) PT4121007T (https=)
RS (1) RS67249B1 (https=)
SI (1) SI4121007T1 (https=)
SM (1) SMT202500350T1 (https=)
WO (1) WO2021186245A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
AU2022307687A1 (en) 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
JP2025539394A (ja) 2022-11-28 2025-12-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 タウｐｅｔレベルを使用する治療の方法
KR20260022396A (ko) 2023-06-09 2026-02-19 에자이 알앤드디 매니지먼트 가부시키가이샤 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Also Published As

Publication number Publication date
PT4121007T (pt) 2025-09-25
LT4121007T (lt) 2025-09-25
BR112022018766A2 (pt) 2022-11-01
CA3174778A1 (en) 2021-09-23
EP4121007B1 (en) 2025-07-02
IL295383B1 (en) 2026-04-01
HUE072937T2 (hu) 2025-12-28
RS67249B1 (sr) 2025-10-31
TW202200201A (zh) 2022-01-01
JP2023518066A (ja) 2023-04-27
PH12022552172A1 (en) 2023-12-11
FI4121007T3 (fi) 2025-09-11
CN115315251A (zh) 2022-11-08
EP4121007A1 (en) 2023-01-25
EP4252777A9 (en) 2024-03-06
MX2022011101A (es) 2022-10-03
PL4121007T3 (pl) 2025-11-03
JP2025111516A (ja) 2025-07-30
WO2021186245A1 (en) 2021-09-23
MA59082B1 (fr) 2025-09-30
CL2022002517A1 (es) 2023-03-24
ES3041762T3 (en) 2025-11-14
SMT202500350T1 (it) 2025-11-10
CL2024003428A1 (es) 2025-04-11
JP7689141B2 (ja) 2025-06-05
HRP20251087T1 (hr) 2025-11-07
SI4121007T1 (sl) 2025-10-30
CO2022012916A2 (es) 2022-09-20
IL295383A (en) 2022-10-01
AU2021238951A1 (en) 2022-10-20
IL326613A (en) 2026-04-01
EP4252777A3 (en) 2024-01-24
DK4121007T3 (da) 2025-09-22
US20230183328A1 (en) 2023-06-15
MD4121007T2 (ro) 2025-11-30
EP4252777A2 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
KR20220156534A (ko) 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법
US20220251210A1 (en) Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
US10472416B2 (en) IL-17 antibody formulations and methods of treatment using same
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
US20210023216A1 (en) Stable aqueous anti-tau antibody formulations
CN114146174B (zh) 抗pd-l1/ox40双特异性抗体制剂及其制备方法和用途
CN115052622B (zh) 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
US20250282882A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
RU2846725C1 (ru) ВЫСОКОКОНЦЕНТРИРОВАННЫЕ СОСТАВЫ НА ОСНОВЕ АНТИТЕЛ К ПРОТОФИБРИЛЛАМ Аβ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20230020449A (ko) 레빌리맙의 수성 약학적 조성물
HK40102754A (en) High concentration anti-ass protofibril antibody formulations and methods of use thereof
BR122025027938A2 (pt) FORMULAÇÕES DE ANTICORPO DE PROTOFIBRILA ANTI-Abeta DE CONCENTRAÇÃO ALTA E MÉTODOS DE USO DAS MESMAS
HK40085437A (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
HK40085437B (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
US20250011411A1 (en) Anti-SOST Antibody Pharmaceutical Composition and Use Thereof
EA045933B1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
HK40093315A (zh) 乐维利单抗的水性药用组合物及其用途
JP2025534054A (ja) 抗ｔｉｇｉｔ抗体を含む製剤及びその使用方法
EA052372B1 (ru) Фармацевтическая композиция, содержащая моноклональное антитело к ox40
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902